Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 498

1.

MMR vaccination and disease elimination: the Finnish experience.

Davidkin I, Kontio M, Paunio M, Peltola H.

Expert Rev Vaccines. 2010 Sep;9(9):1045-53. doi: 10.1586/erv.10.99. Review.

PMID:
20822347
2.

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.

N Engl J Med. 1994 Nov 24;331(21):1397-402.

3.

Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.

Bae GR, Choe YJ, Go UY, Kim YI, Lee JK.

Vaccine. 2013 May 31;31(24):2661-6. doi: 10.1016/j.vaccine.2013.04.014. Epub 2013 Apr 17.

PMID:
23602654
4.

An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.

Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM.

J Infect Dis. 2004 May 1;189 Suppl 1:S131-45.

PMID:
15106102
5.

Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.

J Infect Dis. 2008 Apr 1;197(7):950-6. doi: 10.1086/528993.

PMID:
18419470
6.

Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.

Wang Z, Yan R, He H, Li Q, Chen G, Yang S, Chen E.

PLoS One. 2014 Feb 20;9(2):e89361. doi: 10.1371/journal.pone.0089361. eCollection 2014.

7.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
8.

Progress toward measles and rubella elimination in Egypt.

El Sayed N, Kandeel N, Barakat I, Moussa I, Alexander JP Jr, Naouri B, Reef SE.

J Infect Dis. 2011 Jul;204 Suppl 1:S318-24. doi: 10.1093/infdis/jir123.

PMID:
21666180
9.
10.

Mumps and rubella eliminated from Finland.

Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP.

JAMA. 2000 Nov 22-29;284(20):2643-7.

PMID:
11086376
11.

Measles, mumps and rubella: control by vaccination.

van Druten JA, de Boo T, Plantinga AD.

Dev Biol Stand. 1986;65:53-63.

PMID:
3556777
12.

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.

Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, Litton P, Miller E.

Vaccine. 2002 Jan 15;20(7-8):1134-40.

PMID:
11803074
13.

MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.

Johnson H, Hillary IB, McQuoid G, Gilmer BA.

Vaccine. 1995 Apr;13(6):533-7.

PMID:
7483773
14.

Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.

Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.

Vaccine. 2014 Feb 26;32(10):1147-52. doi: 10.1016/j.vaccine.2014.01.002. Epub 2014 Jan 15.

PMID:
24440207
16.

Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.

Matter HC, Cloetta J, Zimmermann H.

J Epidemiol Community Health. 1995 Aug;49 Suppl 1:4-8.

17.

Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.

Paunio M, Virtanen M, Peltola H, Cantell K, Paunio P, Valle M, Karanko V, Heinonen OP.

Am J Epidemiol. 1991 Jun 1;133(11):1152-60.

PMID:
2035518
18.

Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.

Mahamud A, Masunu-Faleafaga Y, Walls L, Williams N, Garcia P, Teshale E, Williams R, Dulski T, Bellini WJ, Kutty PK.

Vaccine. 2013 Aug 12;31(36):3683-7. doi: 10.1016/j.vaccine.2013.05.102. Epub 2013 Jun 13.

PMID:
23770334
19.

Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.

Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S.

Bone Marrow Transplant. 2004 Jun;33(12):1187-90.

PMID:
15077129
20.

Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.

Heath TC, Burgess MA, O'Brien ED.

Commun Dis Intell. 1998 Aug 6;22(8):159. No abstract available.

Supplemental Content

Support Center